ANAVEON AG’s Post

🌊𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀: 𝘀𝗵𝗶𝗳𝘁𝗶𝗻𝗴 𝘀𝗲𝗮𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺🌊 👫 Christian and Andrea visited the Biosimilars Medicines Conference in Amsterdam, Netherlands, and it was an insightful experience. Our booth was a great way to connect with people, swap industry stories, and get inspired for what's next. 🔍𝗢𝘂𝗿 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆? 🔄 The #biosimilars market is changing tides. With patents expiring or being extended at various times, the market is now experiencing a more punctual pattern of new biosimilar introductions, rather than the previous wave-like releases. 💼 For Evidentic, this means we're ready to adapt our services to the evolving needs of companies developing full-spectrum biosimilars. We're prepared to reach a wider range of companies developing biosimilars, not just those riding the "patent cliff" wave. #BiosimilarConference #Innovation #Evidentic #Amsterdam #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery

Andaman7 founder and CEO, VincentKeunen, has been featured in the Outsourcing-Pharma end of year review looking at the biggest challenges and opportunities of 2023 and the predicted trends of 2024. Read the article https://bit.ly/a7op-kpt

New look, new solutions. Have you seen our new Biopharma and Pharma web pages? Our new drug discovery research page has you covered from biomarker discovery, to #Met ID and #PROTACs. Learn more https://bit.ly/3RkS0dV #DrugDiscovery #BiomarkerDiscovery #HTS

We are less than a month away from EDDC’s Annual Drug Discovery Symposium 2024 happening on 19 July 2024, Friday! This year, our esteemed speakers will speak on the following topics regarding the transformation of Drug Discovery:  1. William Chin: Evolution of Drug Discovery – Finding Drugs Then and Now  2. Jackie Hunter PhD DSc CBE FBPharmacolS FMedSci: How Bigger Data, Better Questions and AI-driven Tools are Changing Drug Discovery and Development 3. Andreas Wallnoefer: A Short Guidance on Success Factors in Drug Development 4. Alex Matter: The Challenges for Global Healthcare   A reminder that there is a closed-door networking session with the speakers after the event, for a limited number of sign-ups.    Register here: https://lnkd.in/g5x-nMsP   Check out the event webpage for more information: https://lnkd.in/gtrpdpyS  You may also download the full programme booklet on the webpage for more information on the talks and speakers.   We hope to see you there!   #EDDCsg #DrugDiscovery #DrugDevelopment #Symposium #Networking

New look, new solutions. Have you seen our new Biopharma and Pharma web pages? Our new drug discovery research page has you covered from biomarker discovery, to #MetID and #PROTACs. Learn more https://bit.ly/3RkS0dV #DrugDiscovery #BiomarkerDiscovery #HTS

Insightful discussion on the value of partnerships at Executive Insights 2024 Emphasizing that partnerships are critical for successful drug development, especially for small companies like BioArctic that rely on collaborations, Gunilla Osswald, BioArctic CEO, was one of the speakers at the Executive Insights 2024 conference hosted by Cytel, DNB, and Flerie. Osswald values partners who are truly interested in working together cooperatively to achieve strong relationships and added a sixth "R" to the classic 5R concept in pharma negotiations - focusing on the significance of relationships and their ability to advance innovation. The six Rs: - Right target - Right patient population - Right dose and exposure - Right study design - Right safety - Right collaborations

Collaboration: The powerful leverage in Drug Development BioArctic's post highlighting CEO Gunilla Osswald's revised perspective on AstraZeneca's 5R Framework for successful drug development is spot on. As a scientist with 12 years of experience leading Offspring Biosciences, a Tissue Analytics CRO, as well as previously working on the big pharma side overseeing outsourcing of research, I offer my take on this. Synergy through Collaboration: The Power of the 6th R Gunilla's insightful addition of a 6th "R" – Right Collaboration – to the existing 5R framework is a powerful recognition of the critical value CRO partnerships brings to drug development. Indeed, the CRO industry's tremendous expansion during the past 15 years is a direct reflection of the growing need for specialized expertise in today's complex drug development landscape. Beyond Execution: The Embedded Scientific Partner However, maximizing the value of these collaborations hinges on how they are structured and executed. This is where Gunilla Osswald's concept of "Right Collaboration" comes into play. My experience is that the ideal scenario involves the CRO functioning as a truly embedded scientific partner, actively involved in designing, executing, and evaluating studies that drives the projects forward to the next critical decision point. This collaborative approach stands in contrast to operative models for outsourcing where the CROs serve primarily as an extension of the pharma company's lab, executing tasks with limited input. BioArctic’s 6R framework, with its emphasis on Right Collaborations, paves the way for a more symbiotic relationship which leverages the strengths of both pharma and CRO for an accelerated and successful drug development progress. A Shared Journey As scientists and industry professionals, both within pharma and CROs, we share a common goal: advancing the development of safe and effective drugs that brings true value to our common client – the patients. Let's unlock the power of true collaborations, as outlined in the 6R framework, to turn this vision into reality. What do you think? Share your experiences from collaborative CRO partnerships in the comments! #Collaboration #DrugDevelopment https://lnkd.in/dfPpTRgc https://lnkd.in/dgPX22aV

“A one-size-fits-all approach to biopharma R&D no longer fits the technology-savvy, diversified world of drug development.” In a newly published article in the DIA Global Forum, Mary Lynn Mercado (Novartis) and Madhavi Gidh-Jain (Sanofi) share their opinions about the evolving landscape of clinical trials, emphasizing TransCelerate's pivotal role in the collaborative partnership with EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms, which enabled adaptive platform trials through advanced tools and frameworks such as the master protocol template. The article also features perspectives from Peter M. (Novartis) and Cecile Spiertz (Exscientia) on the efforts and development of this protocol. Learn more about the TransCelerate and EU-PEARL collaboration: https://lnkd.in/efzuDWWS

Looking forward to #World Drug Safety Congress Americas in October - Arietta.ai will be showing the latest in Applied AI for #pharmacovigilance

Chemaxon and Certara finally as one company, bringing you the next generation of a more precise, model-informed Drug Discovery and Development, with improved certainty in decision-making throughout. Join us for a live webinar on 20th Nov with Certara's CEO William Feehery and Chemaxon's CEO Richard Jones to learn more and be sure to check out our press release below